TY - JOUR
T1 - Canonical transient receptor potential channels in disease
T2 - targets for novel drug therapy?
AU - Trebak, Mohamed
N1 - Funding Information:
The author acknowledges ideas from Drs Guillermo Vazquez, Demetra Stamm and Jim Putney. Drs David Armstrong, Serena Dudek, Loic Lemonnier, Nadine Hempel and Jeremy Smyth read the manuscript and provided comments. The author's work is supported by the Intramural Program of NIH. This article is dedicated to the memory of Al-hadj Lahçen Trebak.
PY - 2006/10
Y1 - 2006/10
N2 - The canonical transient receptor potential (TRPC) channels constitute one of the three major families within the large transient receptor potential (TRP) superfamily. TRPC channels are the closest mammalian homologues of Drosophila TRP, the light-activated channel in Drosophila photoreceptor cells. All TRPC channels (TRPC1-7) are activated via phospholipase-C-coupled receptors and were, therefore, proposed to encode elusive native receptor-activated cation channels in many cell types. A physiological role has been established for all of the known TRPC channels, including the control of vascular tone (TRPC1, TRPC4 and TRPC6) or lymphocyte activation, which is essential for immune competence (TRPC1 and TRPC3). The emergence of TRPC channels in controlling a variety of biological functions offers new and promising targets for drug development.
AB - The canonical transient receptor potential (TRPC) channels constitute one of the three major families within the large transient receptor potential (TRP) superfamily. TRPC channels are the closest mammalian homologues of Drosophila TRP, the light-activated channel in Drosophila photoreceptor cells. All TRPC channels (TRPC1-7) are activated via phospholipase-C-coupled receptors and were, therefore, proposed to encode elusive native receptor-activated cation channels in many cell types. A physiological role has been established for all of the known TRPC channels, including the control of vascular tone (TRPC1, TRPC4 and TRPC6) or lymphocyte activation, which is essential for immune competence (TRPC1 and TRPC3). The emergence of TRPC channels in controlling a variety of biological functions offers new and promising targets for drug development.
UR - http://www.scopus.com/inward/record.url?scp=33748750152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748750152&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2006.08.002
DO - 10.1016/j.drudis.2006.08.002
M3 - Review article
C2 - 16997143
AN - SCOPUS:33748750152
SN - 1359-6446
VL - 11
SP - 924
EP - 930
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 19-20
ER -